At what pace is the ribose-nucleic acid (rna)-based therapeutics market growing, and what is its estimated value?
The ribose-nucleic acid (RNA)-based therapeutics market size has grown strongly in recent years. It will grow from $15.79 billion in 2024 to $17.26 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to investment and funding growth, the discovery of RNA interference (RNAi), clinical successes of antisense oligonucleotides (ASOs), regulatory support and frameworks, and collaborations, and partnerships.
The ribose-nucleic acid (RNA)-based therapeutics market size is expected to see strong growth in the next few years. It will grow to $24.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to the expansion of indications, rising market demand and adoption, regulatory support, integration of AI and machine learning, and emerging applications in rare diseases. Major trends in the forecast period include advanced delivery systems, multi-target RNA therapeutics, customized RNA therapies, regulatory advancements, and commercialization and market growth.
Get Your Free Sample of The Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18454&type=smp
What are the top drivers to the rising demand in the ribose-nucleic acid (rna)-based therapeutics market?
The increasing prevalence of cancer is expected to propel the growth of the ribose-nucleic acid (RNA)-based therapeutics market going forward. Cancer refers to a condition where abnormal cells grow and spread uncontrollably, potentially leading to death if untreated. The prevalence of cancer is due to an aging population, lifestyle changes, greater exposure to risks, and better detection methods. RNA-based therapeutics offer a promising avenue for cancer treatment by directly targeting the genetic and molecular mechanisms of cancer. For instance, in August 2023, according to the Australian Institute of Health and Welfare, an Australia-based government administration for health, around 151,000 individuals were diagnosed with cancer (excluding basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of the skin) in 2021, which is expected to reach 185,000 in 2030. Therefore, the increasing prevalence of cancer is driving the ribose-nucleic acid (RNA)-based therapeutics market.
How is the ribose-nucleic acid (rna)-based therapeutics market segmented?
The ribose-nucleic acid (RNA)-based therapeutics market covered in this report is segmented –
1) By Type: RNA Interference (RNAi), RNA Antisense
2) By Technology: Enabling Technology, Enabled Technology
3) By Therapeutic Area: Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Other Therapeutic Areas
4) By End User: Research Institutes, Hospitals And Clinics
Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), MicroRNA (miRNA)
2) By RNA Antisense: Antisense Oligonucleotides (ASOs), Antisense RNA
Order your report now for swift delivery
Who are the top competitors in the ribose-nucleic acid (rna)-based therapeutics market?
Major companies operating in the ribose-nucleic acid (RNA)-based therapeutics market are F. Hoffmann-La Roche AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals, Biogen Inc., Houston Methodist Hospital, BioNTech, University of Oxford, Alnylam Pharmaceuticals, Sarepta Therapeutics, Flagship Pioneering, Ionis Pharmaceuticals, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Wave Life Sciences, Pharmaceutical Technology, Quark Pharmaceuticals, Tekmira Pharmaceuticals, ReCode Therapeutics, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Olix Pharmaceuticals, Alltrna Inc., Orbital Therapeutics
What significant trends should we anticipate in the ribose-nucleic acid (rna)-based therapeutics market over the forecast period?
Major companies operating in the ribose nucleic acid (RNA)-based therapeutics market are focused on developing innovative medication solutions, such as messenger RNA (mRNA)-based booster vaccines, to enhance the effectiveness of immunization, address emerging viral variants, and improve the overall durability of vaccine-induced immunity. An mRNA-based booster vaccine uses messenger RNA to prompt cells to create a protein that enhances the body’s immune response against a particular pathogen. For instance, in June 2023, Gennova Biopharmaceuticals Ltd., an India-based pharmaceutical company, launched GEMCOVAC-OM, India’s first mRNA booster vaccine specifically targeting the Omicron variant of COVID-19. This booster is essential due to the limited efficacy of the original vaccines against Omicron. Utilizing mRNA technology, GEMCOVAC-OM boosts immunity and offers enhanced protection against the evolving virus.
Which regional trends are influencing the ribose-nucleic acid (rna)-based therapeutics market, and which area dominates the industry?
North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2024. The regions covered in the ribose-nucleic acid (RNA)-based therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report 2025 Offer?
The ribose-nucleic acid (rna)-based therapeutics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
The ribose-nucleic acid (RNA)-based therapeutics refer to a class of medical treatments that utilize ribose-nucleic acid (RNA) molecules to influence cellular processes, typically by targeting specific genetic sequences. These therapies are designed to treat various conditions, including genetic disorders, cancers, and infectious diseases, by modulating gene expression, protein production, or cellular signaling pathways.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18454
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
